Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 15/20 | 0.73 |
| ▸ | ABCC8 | Q09428 | 15/20 | 0.73 |
| ▸ | KCNJ11 | Q14654 | 15/20 | 0.73 |
| ▸ | KCNJ8 | Q15842 | 15/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929871 | 0.91 | ABCC9 (0.62) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL7833345 | 0.87 | ABCC9 (0.75) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL6909541 | 0.86 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL6432083 | 0.86 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL6903824 | 0.86 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL6903919 | 0.86 | ABCC9 (0.61) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL7239344 | 0.85 | ABCC9 (1.00) | ABCC9ABCC8KCNJ11KCNJ8 | |
| SCHEMBL15450449 | 0.84 | GPR174 (0.71) | GAAGPR174KMT2A | |
| SCHEMBL7817092 | 0.83 | GPR174 (0.70) | ABCC9ABCC8KCNJ11KCNJ8KDM4E | |
| SCHEMBL7820651 | 0.83 | ABCC9 (0.63) | ABCC9ABCC8KCNJ11KCNJ8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118174-A1 | TREATMENT SOLUTION AND METHOD FOR PREVENTING POSTERIOR CAPSULAR OPACIFICATION BY SELECTIVELY INDUCING DETACHMENT AND/OR DEATH OF LENS EPITHELIAL CELLS | ZHANG JINJUN | 2011-05-19 | — | — | US | disclosed |
| US-7875270-B2 | Ion transport mechanism interference agent is capable of interfering with the cellular mechanisms of lens epithelial cells while leaving other ocular cells unharmed | Abbott Medical Optics Inc. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20050159410-A1 | Treatment solution and method for preventing posterior capsular opacification by selectively inducing detachment and/or death of lens epithelial cells | ZHANG, JIN JUN (CN) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885ABCC8 415/4885KCNJ11 18/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885ABCC8 605/4885KCNJ11 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.